Atrial fibrillation the most common cardiac arrhythmia. Its incidence rises steadily with each decade, becoming a real "epidemic phenomenon". Cardioversion is defined as a rhythm control strategy which, if successful, restores normal sinus rhythm. This, whether obtained with synchronized shock or with drugs, involves a periprocedural risk of stroke and systemic embolism which is reduced by adequate anticoagulant therapy in the weeks before or by the exclusion of left atrial thrombi. Direct oral anticoagulants are safe, manageable, and provide rapid onset of oral anticoagulation; they are an important alternative to heparin/warfarin from all points of view, with a considerable reduction in bleedings and increase in the safety and quality of life of patients.
Coppola G., Manno G., Mignano A., Luparelli M., Zarcone A., Novo G., et al. (2019). Management of direct oral anticoagulants in patients with atrial fibrillation undergoing cardioversion. MEDICINA, 55(10), 660 [10.3390/medicina55100660].
Management of direct oral anticoagulants in patients with atrial fibrillation undergoing cardioversion
Coppola G.;Manno G.;Mignano A.;Luparelli M.;Zarcone A.;Novo G.;Corrado E.
2019-01-01
Abstract
Atrial fibrillation the most common cardiac arrhythmia. Its incidence rises steadily with each decade, becoming a real "epidemic phenomenon". Cardioversion is defined as a rhythm control strategy which, if successful, restores normal sinus rhythm. This, whether obtained with synchronized shock or with drugs, involves a periprocedural risk of stroke and systemic embolism which is reduced by adequate anticoagulant therapy in the weeks before or by the exclusion of left atrial thrombi. Direct oral anticoagulants are safe, manageable, and provide rapid onset of oral anticoagulation; they are an important alternative to heparin/warfarin from all points of view, with a considerable reduction in bleedings and increase in the safety and quality of life of patients.File | Dimensione | Formato | |
---|---|---|---|
6. Management of Direct Oral Anticoagulants in CVE.pdf
accesso aperto
Tipologia:
Versione Editoriale
Dimensione
886.12 kB
Formato
Adobe PDF
|
886.12 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.